Investor profile
Isabel Giangrasso
Corporate VC & Sr. Associate - Lilly Venture Capital at Eli Lilly and Company
Isabel Giangrasso is a Sr. Associate - Lilly Venture Capital at Eli Lilly and Company, whose known portfolio counts 19 companies.
Is Isabel Giangrasso a fit for your startup?
Paste your website. AI checks the fit and scores every other investor too.
Investment focus
- Sector
- AIHealthcare
Contacts
Affiliated funds' portfolios
Sr. Associate - Lilly Venture Capital at Eli Lilly and Company, whose known portfolio counts 19 companies
- Haya Therapeutics
- Arda Therapeutics
- Strand Therapeutics
- TRex Bio
- Aktis Oncology
- Elektrofi
- Zephyr AI
- Ajax Therapeutics
- Artax Biopharma
- Circle Pharma
- Sunbird Bio
- Amprion
- and 7 more
Investor Profile
Isabel Giangrasso is listed against sectors AI and Healthcare, and focus areas Biotech, Drug Discovery, Genomics and Machine Learning in the database.
Stage-wise, the deals at Eli Lilly and Company cluster around Growth, Late-Stage and Seed rounds.
What the affiliated firm has backed is the closest available signal on whether Isabel Giangrasso is worth approaching.
Colleagues at Eli Lilly and Company
Showing 20 of 23
Rebecca Canter
Executive Director - Ventures
United Kingdom
Jan Philipp Kruse
Senior Director
Berlin, Germany
Gopika Nair
Investor
San Francisco, United States
David Fink
Senior Director Transactions Venture Development
Indianapolis, United States
Emily Counceller
Investor
Indianapolis, United States
Pulkit Gupta
Executive Director, Lilly Ventures
Cambridge, United States
Bruce Konicek
Sr. Director Lilly Tech Ventures
Carmel, United States
Ekaterina Shchukina
Associate, Lilly Ventures
San Francisco, United States
Austin Bruen
Venture Capital
Indianapolis, United States
Christian Fenske
Venture Investor
Indianapolis, United States
Takao Honda
Senior Director, Lilly New Ventures, Asia
Kobe, Japan
Michelle L.
Director, Lilly Ventures
Boston, United States
Chris Tsakalakis
Group Vice President and CEO, LillyDirect
San Francisco, United States
Yi Li
Sr. Director-Medical-Accelerated R&D Leadership Program
Toronto, Canada
Laura A. Lane
Vice President - Lilly Ventures (Head of Europe)
Oxford, United Kingdom
Andiely Lu
Vice President
Shanghai, China
M. Jaione Maiz
Senior Director
Redwood City, United States
Katie Coulter
Lilly Ventures
Boston, United States
Shah VM
Venture Capitalist
Singapore
Tao Yu
Managing Director
Shenzhen, China
Frequently asked questions
Who is Isabel Giangrasso?
Isabel Giangrasso is a corporate venture investor based in United States, listed as Sr. Associate - Lilly Venture Capital at Eli Lilly and Company. The known portfolio of that firm counts 19 companies. That portfolio belongs to the firm, not to Isabel Giangrasso personally.
What does Isabel Giangrasso invest in?
Listed sectors include AI and Healthcare; listed focus areas include Biotech, Drug Discovery, Genomics and Machine Learning. Those tags come from the portfolios of the firms this profile is attached to, so they read as a record of what has been backed rather than a stated preference for what comes next.
What stage does Isabel Giangrasso invest at?
Eli Lilly and Company appears in Growth, Late-Stage and Seed rounds across its known deals, and Isabel Giangrasso is listed there as Sr. Associate - Lilly Venture Capital. Stage is the strongest single filter when you build a target list: an investor with no record at your stage rarely starts with you.
Which firm is Isabel Giangrasso listed at?
Isabel Giangrasso is listed as Sr. Associate - Lilly Venture Capital at Eli Lilly and Company. 23 other people in the database share a firm with Isabel Giangrasso.
How do I contact Isabel Giangrasso?
A LinkedIn page is on file for Isabel Giangrasso. It is readable inside RaiseHunt after you create an account. The database holds no email address and no phone number for this profile.
Skip the browsing. Let AI find your ideal investors in one minute.
Paste your startup website and AI picks your best-fit investors out of 135,000+ profiles.
Data: RaiseHunt investor dataset · Snapshot 5 September 2026 · How this data is built · Report a correction or request removal